GeoVax Labs Stock Price, News & Analysis (NASDAQ:GOVX) $0.43 0.00 (0.00%) (As of 11/30/2023 ET) Add Compare Share Share Today's Range$0.41▼$0.4450-Day Range$0.43▼$0.5952-Week Range$0.41▼$1.39Volume187,936 shsAverage Volume722,290 shsMarket Capitalization$11.44 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media GeoVax Labs MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,300.2% Upside$6.00 Price TargetShort InterestHealthy2.38% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.77Based on 6 Articles This WeekInsider TradingAcquiring Shares$5,020 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.73) to ($0.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.28 out of 5 starsMedical Sector272nd out of 949 stocksPharmaceutical Preparations Industry107th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingGeoVax Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, GeoVax Labs has a forecasted upside of 1,300.2% from its current price of $0.43.Amount of Analyst CoverageGeoVax Labs has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.38% of the outstanding shares of GeoVax Labs have been sold short.Short Interest Ratio / Days to CoverGeoVax Labs has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeoVax Labs has recently decreased by 24.22%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGeoVax Labs does not currently pay a dividend.Dividend GrowthGeoVax Labs does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GOVX. Previous Next 2.1 News and Social Media Coverage News SentimentGeoVax Labs has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for GeoVax Labs this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GeoVax Labs insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,020.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of GeoVax Labs is held by insiders.Percentage Held by InstitutionsOnly 6.09% of the stock of GeoVax Labs is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for GeoVax Labs are expected to grow in the coming year, from ($0.73) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeoVax Labs is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeoVax Labs is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeoVax Labs has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About GeoVax Labs Stock (NASDAQ:GOVX)GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Read More GOVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GOVX Stock News HeadlinesNovember 30, 2023 | finance.yahoo.comGeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine CongressNovember 29, 2023 | finance.yahoo.comGeoVax to Participate in Upcoming December Investor EventsDecember 1, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 28, 2023 | finance.yahoo.comGeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine CongressNovember 27, 2023 | msn.comGeovax Labs (GOVX) Price Target Increased by 12.50% to 6.12November 10, 2023 | finance.yahoo.comGeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finanznachrichten.deGeoVax, Inc.: GeoVax Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 7, 2023 | benzinga.comGeovax Labs Earnings PreviewDecember 1, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!October 31, 2023 | finance.yahoo.comGeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023October 24, 2023 | finance.yahoo.comGeoVax Update: Clinical and Operational Progress Toward Transformative OpportunitiesOctober 5, 2023 | finanznachrichten.deGeoVax, Inc.: GeoVax Receives Notice of Allowance for HIV Vaccine PatentSeptember 27, 2023 | finance.yahoo.comGeoVax to Participate in Upcoming October Investor and Industry EventsSeptember 26, 2023 | markets.businessinsider.comGeoVax Labs Secures License Agreement With ProBioGenSeptember 19, 2023 | finance.yahoo.comGeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised PatientsSeptember 12, 2023 | finance.yahoo.comGeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 11, 2023 | finance.yahoo.comGeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine BoosterAugust 31, 2023 | msn.comGeovax Labs (GOVX) Price Target Increased by 11.11% to 6.12August 31, 2023 | finance.yahoo.comGeoVax to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 28, 2023 | finanznachrichten.deGeoVax, Inc.: GeoVax Receives Notice of Allowance for Malaria Vaccine PatentAugust 11, 2023 | finance.yahoo.comGeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2023 Earnings Call TranscriptJuly 26, 2023 | finance.yahoo.comGeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023July 24, 2023 | markets.businessinsider.comGeoVax Labs (GOVX) Gets a Buy from Noble FinancialJuly 24, 2023 | finance.yahoo.comGeoVax Announces Issuance of Ebola Vaccine PatentJuly 20, 2023 | finanznachrichten.deGeoVax, Inc.: GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic LeukemiaJuly 20, 2023 | finance.yahoo.comGeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic LeukemiaJune 28, 2023 | finance.yahoo.comGeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer ConferenceSee More Headlines Receive GOVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today11/30/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GOVX CUSIPN/A CIK832489 Webwww.geovax.com Phone(678) 384-7220Fax678-384-7281Employees14Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$8.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,300.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,020,000.00 Net MarginsN/A Pretax Margin-2,375,800.00% Return on Equity-126.41% Return on Assets-99.54% Debt Debt-to-Equity RatioN/A Current Ratio2.09 Quick Ratio2.09 Sales & Book Value Annual Sales$80,000.00 Price / Sales142.96 Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book1.26Miscellaneous Outstanding Shares26,690,000Free Float25,627,000Market Cap$11.44 million OptionableNot Optionable Beta2.93 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. David Alan Dodd (Age 73)Chairman, President & CEO Comp: $469.01kMr. Mark W. Reynolds CPA (Age 61)CFO & Corporate Secretary Comp: $348.2kDr. Mark J. Newman Ph.D. (Age 68)Chief Scientific Officer Comp: $364.17kDr. Harriet Latham Robinson Ph.D. (Age 85)Founder & Member of Scientific Advisory Board Dr. Kelly T. McKee Jr. (Age 73)M.D., M.P.H., Chief Medical Officer Jeffrey WelchHead of Process Development & Manufacturing OperationsDr. John W. Sharkey Ph.D. (Age 67)Vice President of Business Development More ExecutivesKey CompetitorsMustang BioNASDAQ:MBIOCNS PharmaceuticalsNASDAQ:CNSPAcelRx PharmaceuticalsNASDAQ:ACRXBionomicsNASDAQ:BNOXProcessa PharmaceuticalsNASDAQ:PCSAView All CompetitorsInsidersKelly T Jr. MckeeBought 9,653 shares on 9/25/2023Total: $5,019.56 ($0.52/share)David A DoddBought 35,087 shares on 8/25/2023Total: $19,999.59 ($0.57/share)Mark ReynoldsBought 10,000 shares on 8/18/2023Total: $5,200.00 ($0.52/share)David A DoddBought 32,000 shares on 4/24/2023Total: $20,480.00 ($0.64/share)Mark ReynoldsBought 8,000 shares on 4/20/2023Total: $5,040.00 ($0.63/share)View All Insider Transactions GOVX Stock Analysis - Frequently Asked Questions Should I buy or sell GeoVax Labs stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GeoVax Labs in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GOVX shares. View GOVX analyst ratings or view top-rated stocks. What is GeoVax Labs' stock price target for 2024? 2 brokers have issued 1 year target prices for GeoVax Labs' shares. Their GOVX share price targets range from $4.00 to $8.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,300.2% from the stock's current price. View analysts price targets for GOVX or view top-rated stocks among Wall Street analysts. How have GOVX shares performed in 2023? GeoVax Labs' stock was trading at $0.6302 at the beginning of 2023. Since then, GOVX shares have decreased by 32.0% and is now trading at $0.4285. View the best growth stocks for 2023 here. Are investors shorting GeoVax Labs? GeoVax Labs saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 634,200 shares, a decrease of 24.2% from the October 31st total of 836,900 shares. Based on an average trading volume of 214,700 shares, the days-to-cover ratio is currently 3.0 days. View GeoVax Labs' Short Interest. When is GeoVax Labs' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our GOVX earnings forecast. How were GeoVax Labs' earnings last quarter? GeoVax Labs, Inc. (NASDAQ:GOVX) posted its earnings results on Wednesday, November, 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.15. How do I buy shares of GeoVax Labs? Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:GOVX) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.